Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/009047ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
WO 21.01.2021
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/EP2020/069561 Applicant F. HOFFMANN-LA ROCHE AG Inventor UMAÑA, Pablo
The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.
2.WO/2021/009422METHOD FOR SELF-ASSEMBLY OF A PROTEIN ON A SUBSTRATE IN A THREE-DIMENSIONAL HONEYCOMB STRUCTURE
WO 21.01.2021
Int.Class C07K 14/415
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
415from plants
Appl.No PCT/FR2020/050932 Applicant COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Inventor ELCHINGER, Pierre-Henri
Method for self-assembly of a protein in a three-dimensional honeycomb structure, comprising the following consecutive steps: - providing a solution comprising a solvent and a protein, the protein comprising a sequence of amino acids corresponding to an oligomerisation domain of a LEAFY protein, for example to the oligomerisation domain of Ginkgo biloba, in fusion with a tag, - placing the solution in contact with a substrate, - evaporating the solvent in order to crystallise the protein, the oligomerisation domain crystallising in the form of a primary helix, each primary helix interacting with six other primary helixes, whereby a three-dimensional honeycomb protein structure is obtained perpendicular to the substrate, the protein structure being attached to the substrate by the tag.
3.WO/2021/009692TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE
WO 21.01.2021
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/IB2020/056657 Applicant MEDIMMUNE LIMITED Inventor BAMBER, Lisa
The disclosure provides compositions and methods that make use of a target protein that is capable of binding to a small molecule in order to form a complex, and a binding member that specifically binds to the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein may be derived from a viral, bacterial, fungal or protozoal protein. These compositions and methods permit the controlled interaction of polypeptides that are individually fused to the target protein and binding member, respectively, and can be used to control the activity of dimerization-inducible proteins such as split transcription factors and split chimeric antigen receptors through the addition of the small molecule. The disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems and methods that involve these components.
4.WO/2021/010532METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF NOVEL INTERMEDIATE
WO 21.01.2021
Int.Class C07K 14/575
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
Appl.No PCT/KR2019/008912 Applicant HANMI PHARM. CO., LTD. Inventor SHIN, Cheongbyeol
The present invention relates to a novel method for preparing a long-acting drug conjugate, and a long-acting drug conjugate prepared by the method.
5.WO/2021/010712ANTI-TAU ANTIBODY AND USE OF SAME
WO 21.01.2021
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/KR2020/009207 Applicant ADEL, INC. Inventor YOON, Seung-Yong
The present invention relates to an anti-tau antibody specifically binding to a tau protein, and a use of same. The anti-tau antibody according to the present invention specifically binds to a tau protein in which lysine at position 280 is acetylated and can suppress abnormal aggregation of tau proteins. In addition, the anti-tau antibody according to the present invention, when administered to an animal model of induced dementia, can improve locomotor activity and cognitive ability in the animal model. Therefore, the anti-tau antibody according to the present invention may be utilized in the prevention or treatment of neurodegenerative diseases.
6.WO/2021/011417CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
WO 21.01.2021
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
Appl.No PCT/US2020/041710 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor CRAIK, Charles S.
The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.
7.WO/2021/011912COMBINATION OF INTEGRIN-TARGETING KNOTTIN-FC FUSION AND ANTI-CD47 ANTIBODY FOR THE TREATMENT OF CANCER
WO 21.01.2021
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2020/042644 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor COCHRAN, Jennifer R.
The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein in combination with an SIRPα-CD47 immune checkpoint inhibitor, for example an anti-CD47 antibody or an anti-SIRPα-antibody. The invention also provides composition for use in such methods.
8.WO/2021/011927COMPLEMENT INHIBITOR DOSING REGIMENS
WO 21.01.2021
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/US2020/042676 Applicant APELLIS PHARMACEUTICALS, INC. Inventor DESCHATELETS, Pascal
Methods and compositions for inhibiting complement are described.
9.WO/2021/010531NOVEL METHOD FOR PREPARING PROTEIN CONJUGATE
WO 21.01.2021
Int.Class C07K 14/575
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
Appl.No PCT/KR2019/008911 Applicant HANMI PHARM. CO., LTD. Inventor SHIN, Cheongbyeol
The present invention relates to a novel method for preparing a protein conjugate, and a protein conjugate prepared by the method.
10.WO/2021/010621PEPTIDE THERAPEUTICS FOR AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
WO 21.01.2021
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
Appl.No PCT/KR2020/008536 Applicant AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor CHOI, Sang Dun
The present invention relates to a peptide inhibiting a Toll-like receptor (TLR) signaling pathway. More specifically, the present invention relates to: a peptide that strongly binds to a TIR-containing molecule to inhibit the TLR, in particular, the TLR4 signaling pathway; a fusion peptide in which a cell-penetrating peptide is conjugated to said peptide; a TLR4 antagonist comprising said peptide or said fusion peptide; and a composition for preventing or treating autoimmune diseases or inflammatory diseases comprising said peptide or said fusion peptide. According to the present invention, said peptide exhibits an inhibitory effect on a wide range of TLR signaling pathways including TLR4, blocks MyD88- and TRIF-dependent TLR4 pathways, and has a substantial disease-alleviating effect in mouse models of rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and non-alcoholic steatohepatitis, and thus can be usefully utilized as therapeutics for immune-related diseases and inflammatory diseases that require negative control of TLR.